{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:15:45Z","timestamp":1792512945525,"version":"4.5.0"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T00:00:00Z","timestamp":1649721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903672"],"award-info":[{"award-number":["81903672"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014764","name":"China International Medical Foundation","doi-asserted-by":"publisher","award":["Z-2018-35-2003"],"award-info":[{"award-number":["Z-2018-35-2003"]}],"id":[{"id":"10.13039\/501100014764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial iron transport systems facilitating drug entry into cells, achieving high periplasmic concentrations. This systematic review analyzed the currently available literature on cefiderocol. It summarized\n                    <jats:italic>in vitro<\/jats:italic>\n                    susceptibility data,\n                    <jats:italic>in vivo<\/jats:italic>\n                    antimicrobial activity, pharmacokinetics\/pharmacodynamics (PK\/PD), clinical efficacy, safety and resistance mechanisms of cefiderocol. Cefiderocol has potent\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    activity against multidrug-resistant (MDR) Gram-negative bacteria, including carbapenem-resistant isolates. But New Delhi Metallo-\u03b2-lactamase (NDM)- positive isolates showed significantly higher MICs than other carbapenemase-producing\n                    <jats:italic>Enterobacterales<\/jats:italic>\n                    , with a susceptible rate of 83.4% for cefiderocol. Cefiderocol is well-tolerated, and the PK\/PD target values can be achieved using a standard dose regimen or adjusted doses according to renal function. Clinical trials demonstrated that cefiderocol was non-inferiority to the comparator drugs in treating complicated urinary tract infection and nosocomial pneumonia. Case reports and series showed that cefiderocol was a promising therapeutic agent in carbapenem-resistant infections. However, resistant isolates and reduced susceptibility during treatment to cefiderocol have already been reported. In conclusion, cefiderocol is a promising powerful weapon for treating MDR recalcitrant infections.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.896971","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T01:33:00Z","timestamp":1649727180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":50,"title":["Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence"],"prefix":"10.3389","volume":"13","author":[{"given":"Chuanhai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentao","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e0264620","DOI":"10.1128\/AAC.02646-20","article-title":"In Vitro antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter Baumannii","volume":"65","author":"Abdul-Mutakabbir","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e01872","DOI":"10.1128\/AAC.01872-19","article-title":"Long-Term Compassionate Use of Cefiderocol to Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-\u03b2-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient","volume":"64","author":"Alamarat","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e00966","DOI":"10.1128\/JCM.00966-20","article-title":"Comparison of agar Dilution to Broth Microdilution for Testing In Vitro Activity of Cefiderocol against Gram-Negative Bacilli","volume":"59","author":"Albano","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.ejmech.2018.06.014","article-title":"Cefiderocol (S-649266), A New Siderophore Cephalosporin Exhibiting Potent Activities against Pseudomonas aeruginosa and Other Gram-Negative Pathogens Including Multi-Drug Resistant Bacteria: Structure Activity Relationship","volume":"155","author":"Aoki","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria (CREDIBLE-CR): a Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/antibiotics10060652","article-title":"Cefiderocol-based Combination Therapy for \"Difficult-To-Treat\" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/23744235.2020.1856921","article-title":"Recurrent Neurosurgical Site Infection by Extensively Drug-Resistant P. aeruginosa Treated with Cefiderocol: a Case Report and Literature Review","volume":"53","author":"Bavaro","year":"2021","journal-title":"Infect. Dis. (Lond)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"115327","DOI":"10.1016\/j.diagmicrobio.2021.115327","article-title":"In Vitro activity of Cefepime\/zidebactam (WCK 5222) against Recent Gram-Negative Isolates Collected from High Resistance Settings of Greek Hospitals","volume":"100","author":"Bhagwat","year":"2021","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e00559","DOI":"10.1128\/AAC.00559-20","article-title":"Activity of Cefiderocol Alone and in Combination with Levofloxacin, Minocycline, Polymyxin B, or Trimethoprim-Sulfamethoxazole against Multidrug-Resistant Stenotrophomonas Maltophilia","volume":"64","author":"Biagi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10096-021-04341-z","article-title":"In Vitro activity of Cefiderocol against Ceftazidime-Avibactam Susceptible and Resistant KPC-Producing Enterobacterales: Cross-Resistance and Synergistic Effects","volume":"41","author":"Bianco","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/microorganisms9020282","article-title":"Susceptibility Testing Is Key for the success of Cefiderocol Treatment: A Retrospective Cohort Study","volume":"9","author":"Bleibtreu","year":"2021","journal-title":"Microorganisms"},{"key":"B12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40121-020-00385-4","article-title":"Salvage Treatment with Cefiderocol Regimens in Two Intravascular Foreign Body Infections by MDR Gram-Negative Pathogens, Involving Non-removable Devices","volume":"10","author":"Bodro","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jgar.2021.09.005","article-title":"Successful Prolonged Cefiderocol Treatment of a Chronic Left Pleural Empyema Caused by Pseudomonas aeruginosa in a Patient Affected by COVID-19: a Case Report","volume":"27","author":"Borghesi","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e00685","DOI":"10.1128\/AAC.00685-20","article-title":"Burkholderia Pseudomallei Clinical Isolates Are Highly Susceptible In Vitro to Cefiderocol, a Siderophore Cephalosporin","volume":"65","author":"Burnard","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2021.07.018","article-title":"In Vitro activity of the Novel Siderophore Cephalosporin, Cefiderocol, in Gram-Negative Pathogens in Europe by Site of Infection","volume":"28","author":"Candel","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/milmed\/usab350","article-title":"Carbapenem-resistant Enterobacterales Infection after Massive Blast Injury: Use of Cefiderocol Based Combination Therapy","volume":"186","author":"Carney","year":"2021","journal-title":"Mil. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jgar.2021.06.011","article-title":"In Vitro activity of Cefiderocol and Comparators against Isolates of Gram-Negative Bacterial Pathogens from a Range of Infection Sources: SIDERO-WT-2014-2018 S-tudies in Spain","volume":"26","author":"Cercenado","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B18","doi-asserted-by":"publisher","first-page":"i18","DOI":"10.1093\/jacamr\/dlab054","article-title":"Education: A Compassionate Use of Cefiderocol to Treat Osteomyelitis Caused by an XDR Pseudomonas aeruginosa","volume":"3","author":"Chavda","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e01558","DOI":"10.1128\/AAC.01558-19","article-title":"Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas Maltophilia in the Murine Thigh Model","volume":"63","author":"Chen","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1473-3099(21)00194-8","article-title":"Widespread Cefiderocol Heteroresistance in Carbapenem-Resistant Gram-Negative Pathogens","volume":"21","author":"Choby","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijid.2021.06.035","article-title":"Cefiderocol Treatment of Pseudomonas aeruginosa and Extensively Drug-Resistant Acinetobacter Baumannii Retained Spinal Hardware Infection Causing Reversible Acute Interstitial Nephritis: Recto: Cefiderocol Causing Acute Interstitial Nephritis","volume":"109","author":"Cipko","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B22","volume-title":"M100 Performance Standards for Antimicrobial Susceptibility Testing","year":"2020"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e00948","DOI":"10.1128\/AAC.00948-19","article-title":"Coinfections of Two Strains of NDM-1- and OXA-232-Coproducing klebsiella Pneumoniae in a Kidney Transplant Patient","volume":"64","author":"Contreras","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"ofaa150","DOI":"10.1093\/ofid\/ofaa150","article-title":"Case Report: Successful rescue Therapy of Extensively Drug-Resistant Acinetobacter Baumannii Osteomyelitis with Cefiderocol","volume":"7","author":"Dagher","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e00181","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial Resistance in ESKAPE Pathogens","volume":"33","author":"De Oliveira","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1093\/jac\/dkaa117","article-title":"Activity of Cefiderocol against High-Risk Clones of Multidrug-Resistant Enterobacterales, Acinetobacter Baumannii, Pseudomonas aeruginosa and Stenotrophomonas Maltophilia","volume":"75","author":"Delgado-Valverde","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the Novel Siderophore Cephalosporin Cefiderocol against Multidrug-Resistant Gram-Negative Pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1093\/cid\/ciy963","article-title":"Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-Resistant Pseudomonas aeruginosa","volume":"68","author":"Edgeworth","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1093\/jac\/dkx049","article-title":"Activity of Cefiderocol (S-649266) against Carbapenem-Resistant Gram-Negative Bacteria Collected from Inpatients in Greek Hospitals","volume":"72","author":"Falagas","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue Therapy for Acinetobacter Baumannii and Other Carbapenem-Resistant Gram-Negative Infections in Intensive Care Unit Patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B31","volume-title":"Fetroja (Cefiderocol for Injection) Drug","author":"Fetroja (Cefiderocol)","year":"2021"},{"key":"B32","doi-asserted-by":"publisher","first-page":"106395","DOI":"10.1016\/j.ijantimicag.2021.106395","article-title":"Optimised Cefiderocol Exposures in a Successfully Treated Critically Ill Patient with Polymicrobial Stenotrophomonas Maltophilia Bacteraemia and Pneumonia Receiving Continuous Venovenous Haemodiafiltration","volume":"58","author":"Fratoni","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgar.2021.07.014","article-title":"In Vitro activity of Cefiderocol and Comparators against Gram-Negative Bacterial Isolates from a Series of Surveillance Studies in England: 2014-2018","volume":"27","author":"Gant","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000487441","article-title":"Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained In Vivo Activity against Siderophore-Resistant Pseudomonas aeruginosa","volume":"101","author":"Ghazi","year":"2018","journal-title":"Pharmacology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ijantimicag.2017.10.008","article-title":"Pharmacodynamics of Cefiderocol, a Novel Siderophore Cephalosporin, in a Pseudomonas aeruginosa Neutropenic Murine Thigh Model","volume":"51","author":"Ghazi","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/jac\/dkab221","article-title":"Discrepancy in Sustained Efficacy and Resistance Emergence under Human-Simulated Exposure of Cefiderocol against Stenotrophomonas Maltophilia between In Vitro Chemostat and In Vivo Murine Infection Models","volume":"76","author":"Gill","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"115012","DOI":"10.1016\/j.diagmicrobio.2020.115012","article-title":"In Vitro activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in canadian Intensive Care Units","volume":"97","author":"Golden","year":"2020","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.medmal.2020.10.022","article-title":"Compassionate Use of Cefiderocol in a Pancreatic Abscess and Emergence of Resistance","volume":"51","author":"Grande Perez","year":"2021","journal-title":"Infect. Dis. Now"},{"key":"B39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jgar.2021.04.025","article-title":"Compassionate Use of Cefiderocol for VIM Metallo-\u03b2-Lactamase-Producing Pseudomonas aeruginosa Infection in a Toddler with Burkitt Lymphoma","volume":"26","author":"Grasa","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e00093","DOI":"10.1128\/AAC.00093-17","article-title":"In Vitro activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)","volume":"61","author":"Hackel","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e01968","DOI":"10.1128\/AAC.01968-17","article-title":"In Vitro activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016","volume":"62","author":"Hackel","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.cmi.2021.04.016","article-title":"Cross-resistance to Cefiderocol and Ceftazidime-Avibactam in KPC \u03b2-lactamase Mutants and the Inoculum Effect","volume":"27","author":"Hobson","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"B43","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jgar.2021.02.004","article-title":"Clinical Efficacy and Safety of Cefiderocol in the Treatment of Acute Bacterial Infections: A Systematic Review and Meta-Analysis of Randomised Controlled Trials","volume":"24","author":"Hsueh","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B44","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/jac\/dky425","article-title":"In Vitro activities of Cefiderocol, Ceftolozane\/tazobactam, Ceftazidime\/avibactam and Other Comparative Drugs against Imipenem-Resistant Pseudomonas aeruginosa and Acinetobacter Baumannii, and Stenotrophomonas Maltophilia, All Associated with Bloodstream Infections in Taiwan","volume":"74","author":"Hsueh","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"S324","DOI":"10.1093\/ofid\/ofz360.78910.1093\/ofid\/ofz360.796","article-title":"In Vitro activity of Cefiderocol against Gram-Negative Clinical Isolates from New York City","volume":"6","author":"Iregui","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B46","article-title":"Characterization of Isolates Showing High MICs to Cefiderocol from Global Surveillance Study SIDERO-CR-2014\/2016","author":"Ito","year":"2019"},{"key":"B47","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jac\/dkv402","article-title":"In Vitro antimicrobial Activity of S-649266, a Catechol-Substituted Siderophore Cephalosporin, when Tested against Non-fermenting Gram-Negative Bacteria","volume":"71","author":"Ito","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"B48","article-title":"S-649266, a Novel Siderophore Cephalosporin: In Vitro Activity against Gram-Negative Bacteria Including Carbapenem Resistant Strains","author":"Ito","year":"2015"},{"key":"B49","doi-asserted-by":"publisher","first-page":"S251","DOI":"10.1093\/ofid\/ofy210.703","article-title":"696. Mechanism of Cefiderocol High MIC Mutants Obtained in Non-clinical FoR Studies","volume":"5","author":"Ito","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"S418","DOI":"10.1093\/ofid\/ofy210.1197","article-title":"1366. In Vitro and In Vivo Activity of Cefiderocol against Stenotrophomonas Maltophilia Clinical Isolates","volume":"5","author":"Ito","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e01801","DOI":"10.1128\/AAC.01801-18","article-title":"ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum \u03b2-Lactamases and Carbapenemases","volume":"63","author":"Jacobs","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e00797","DOI":"10.1128\/AAC.00797-20","article-title":"Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"115314","DOI":"10.1016\/j.diagmicrobio.2021.115314","article-title":"Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Extended-Spectrum Cephalosporin-Resistant Escherichia coli Clinical Isolates (2012-20017) in Relation to Phylogenetic Background, Sequence Type 131 Subclones, blaCTX-M Genotype, and Coresistance","volume":"100","author":"Johnston","year":"2021","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e00576","DOI":"10.1128\/AAC.00576-17","article-title":"Susceptibility of Imipenem-Susceptible but Meropenem-Resistant blaIMP-6-Carrying Enterobacteriaceae to Various Antibacterials, Including the Siderophore Cephalosporin Cefiderocol","volume":"61","author":"Kanazawa","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ijantimicag.2018.11.007","article-title":"In Vitro activity of Cefiderocol, a Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015","volume":"53","author":"Karlowsky","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B56","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a Siderophore Cephalosporin for Gram-Negative Bacterial Infections: Pharmacokinetics and Safety in Subjects with Renal Impairment","volume":"57","author":"Katsube","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"S330","DOI":"10.1093\/ofid\/ofz360.807","article-title":"Prediction of Cefiderocol Pharmacokinetics and Probability of Target Attainment in Pediatric Subjects for Proposing Dose Regimens","volume":"6","author":"Katsube","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00228-018-2458-9","article-title":"Drug-drug Interaction of Cefiderocol, a Siderophore Cephalosporin, via Human Drug Transporters","volume":"74","author":"Katsube","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1093\/jac\/dkab280","article-title":"Intrapulmonary Pharmacokinetic Profile of Cefiderocol in Mechanically Ventilated Patients with Pneumonia","volume":"76","author":"Katsube","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1093\/jac\/dkz123","article-title":"Intrapulmonary Pharmacokinetics of Cefiderocol, a Novel Siderophore Cephalosporin, in Healthy Adult Subjects","volume":"74","author":"Katsube","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e01381","DOI":"10.1128\/AAC.01381-16","article-title":"Pharmacokinetic\/pharmacodynamic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function","volume":"61","author":"Katsube","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B62","doi-asserted-by":"publisher","first-page":"e01391","DOI":"10.1128\/AAC.01391-17","article-title":"Population Pharmacokinetic Analysis of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Healthy Subjects, Subjects with Various Degrees of Renal Function, and Patients with Complicated Urinary Tract Infection or Acute Uncomplicated Pyelonephritis","volume":"62","author":"Kawaguchi","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B63","doi-asserted-by":"publisher","first-page":"e01437","DOI":"10.1128\/AAC.01437-20","article-title":"Population Pharmacokinetic and Pharmacokinetic\/pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection\/sepsis, or Complicated Urinary Tract Infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B64","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","article-title":"In Vitro activity of Cefiderocol, a Siderophore Cephalosporin, against a Recent Collection of Clinically Relevant Carbapenem-Non-Susceptible Gram-Negative Bacilli, Including Serine Carbapenemase- and Metallo-\u03b2-Lactamase-Producing Isolates (SIDERO-WT-2014 Study)","volume":"53","author":"Kazmierczak","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e01961","DOI":"10.1128\/AAC.01961-19","article-title":"Development of Neutropenic Murine Models of Iron Overload and Depletion to Study the Efficacy of Siderophore-Antibiotic Conjugates","volume":"64","author":"Kidd","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e01767","DOI":"10.1128\/AAC.01767-19","article-title":"Efficacy of Humanized Cefiderocol Exposure Is Unaltered by Host Iron Overload in the Thigh Infection Model","volume":"64","author":"Kidd","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciab511","article-title":"Rapid Development of Cefiderocol Resistance in Carbapenem-Resistant Enterobacter cloacae during Therapy Is Associated with Heterogeneous Mutations in the Catecholate Siderophore Receptor Cira","volume":"74","author":"Klein","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"ofab252","DOI":"10.1093\/ofid\/ofab252","article-title":"Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration","volume":"8","author":"Kobic","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","article-title":"Reduced Susceptibility Mechanism to Cefiderocol, a Siderophore Cephalosporin, Among Clinical Isolates from a Global Surveillance Programme (SIDERO-WT-2014)","volume":"22","author":"Kohira","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B70","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1128\/AAC.01695-15","article-title":"In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains","volume":"60","author":"Kohira","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B71","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/antibiotics10060649","article-title":"Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance","volume":"10","author":"K\u00f6nig","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B72","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41579-019-0284-4","article-title":"Bacterial Siderophores in Community and Host Interactions","volume":"18","author":"Kramer","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"106128","DOI":"10.1016\/j.ijantimicag.2020.106128","article-title":"In Vitro activity of Cefiderocol against Aerobic Gram-Negative Bacterial Pathogens from Germany","volume":"56","author":"Kresken","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e00863","DOI":"10.1016\/j.idcr.2020.e00863","article-title":"Cefiderocol for Treatment of an Empyema Due to Extensively Drug-Resistant Pseudomonas aeruginosa: Clinical Observations and Susceptibility Testing Considerations","volume":"21","author":"Kufel","year":"2020","journal-title":"IDCases"},{"key":"B75","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jgar.2020.10.008","article-title":"Cefiderocol in the Treatment of Systemic Carbapenemase-Producing Multidrug-Resistant Klebsiella pneumoniae Infection","volume":"23","author":"Lampejo","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B76","doi-asserted-by":"publisher","first-page":"106377","DOI":"10.1016\/j.ijantimicag.2021.106377","article-title":"In-vitro Activity of Cefiderocol, Cefepime\/zidebactam, Cefepime\/enmetazobactam, Omadacycline, Eravacycline and Other Comparative Agents against Carbapenem-Nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020","volume":"58","author":"Lee","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B77","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1473-3099(06)70580-1","article-title":"Colistin: the Re-emerging Antibiotic for Multidrug-Resistant Gram-Negative Bacterial Infections","volume":"6","author":"Li","year":"2006","journal-title":"Lancet Infect. Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"00186","DOI":"10.1016\/j.jmii.2021.08.012","article-title":"In Vitro activity of Cefiderocol, Cefepime\/enmetazobactam, Cefepime\/zidebactam, Eravacycline, Omadacycline, and Other Comparative Agents against Carbapenem-Non-Susceptible Pseudomonas aeruginosa and Acinetobacter Baumannii Isolates Associated from Bloodstream Infection in Taiwan between 2018-2020","author":"Liu","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"B79","doi-asserted-by":"publisher","first-page":"dlaa060","DOI":"10.1093\/jacamr\/dlaa060","article-title":"In Vitro activity of the Siderophore Cephalosporin, Cefiderocol, against Molecularly Characterized, Carbapenem-Non-Susceptible Gram-Negative Bacteria from Europe","volume":"2","author":"Longshaw","year":"2020","journal-title":"JAC Antimicrob. Resist."},{"key":"B80","doi-asserted-by":"publisher","first-page":"i21","DOI":"10.1093\/jacamr\/dlab055","article-title":"Compassionate Use of Cefiderocol for Carbapenem-Resistant Acinetobacter Baumannii Prosthetic Joint Infection","volume":"3","author":"Mabayoje","year":"2021","journal-title":"JAC Antimicrob. Resist."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e01221","DOI":"10.1128\/AAC.01221-20","article-title":"Cefiderocol Resistance in Acinetobacter Baumannii: Roles of \u03b2-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3","volume":"64","author":"Malik","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B82","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1136\/jim-2020-SRM.632","article-title":"Investigational Cefiderocol Use in Treatment of Multi-Drug Resistant Achromobacter Spp","volume":"68","author":"Martinez","year":"2021","journal-title":"J. Invest. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"e01128","DOI":"10.1128\/AAC.01128-20","article-title":"Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an In Vitro Chemostat Model","volume":"64","author":"Matsumoto","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B84","doi-asserted-by":"publisher","first-page":"e00700","DOI":"10.1128\/AAC.00700-17","article-title":"Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics","volume":"61","author":"Matsumoto","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B85","doi-asserted-by":"publisher","first-page":"001406","DOI":"10.1099\/jmm.0.001406","article-title":"Pan-drug Resistant Providencia Rettgeri Contributing to a Fatal Case of COVID-19","volume":"70","author":"Mc Gann","year":"2021","journal-title":"J. Med. Microbiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/jcph.1386","article-title":"Metabolism, Excretion, and Pharmacokinetics of [14 C]-cefiderocol (S-649266), a Siderophore Cephalosporin, in Healthy Subjects Following Intravenous Administration","volume":"59","author":"Miyazaki","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"e01022","DOI":"10.1128\/AAC.01022-17","article-title":"Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model","volume":"61","author":"Monogue","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B88","doi-asserted-by":"publisher","first-page":"e01649","DOI":"10.1128\/JCM.01649-20","article-title":"Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-Negative Bacilli: a Comparison of Disk Diffusion to Broth Microdilution","volume":"59","author":"Morris","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e01582","DOI":"10.1128\/AAC.01582-20","article-title":"In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria","volume":"64","author":"Mushtaq","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e02031","DOI":"10.1128\/AAC.02031-18","article-title":"In Vivo pharmacodynamic Study of Cefiderocol, a Novel Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models","volume":"63","author":"Nakamura","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B91","doi-asserted-by":"publisher","first-page":"e01436","DOI":"10.1128\/AAC.01436-20","article-title":"In Vitro activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas Maltophilia","volume":"65","author":"Nakamura","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B92","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jgar.2020.09.019","article-title":"Cefiderocol for Compassionate Use in the Treatment of Complicated Infections Caused by Extensively and Pan-Resistant Acinetobacter Baumannii","volume":"23","author":"Oliva","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B93","doi-asserted-by":"publisher","first-page":"S653","DOI":"10.1093\/ofid\/ofaa439.1457","article-title":"1273. Efficacy of Cefiderocol against Carbapenem-Resistant A. Baumannii and P. aeruginosa in Ventilator-Associated Pneumonia Mouse Model","volume":"7","author":"Ota","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"S529","DOI":"10.1093\/cid\/ciz825","article-title":"The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics","volume":"69","author":"Page","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: an Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B96","doi-asserted-by":"publisher","first-page":"e0087721","DOI":"10.1128\/AAC.00877-21","article-title":"Contribution of PER-type and NDM-type \u03b2-Lactamases to Cefiderocol Resistance in Acinetobacter Baumannii","volume":"65","author":"Poirel","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus Imipenem-Cilastatin for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Uropathogens: a Phase 2, Randomised, Double-Blind, Non-inferiority Trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e01955","DOI":"10.1128\/AAC.01955-19","article-title":"Activity of Cefiderocol and Comparators against Isolates from Cancer Patients","volume":"64","author":"Rolston","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"B99","doi-asserted-by":"publisher","first-page":"e02163","DOI":"10.1128\/AAC.02163-17","article-title":"Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects","volume":"62","author":"Saisho","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1093\/cid\/ciaa355","article-title":"Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime","volume":"71","author":"Shields","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3390\/microorganisms8081236","article-title":"Compassionate Use of Cefiderocol to Treat a Case of Prosthetic Joint Infection Due to Extensively Drug-Resistant Enterobacter Hormaechei","volume":"8","author":"Sim\u00e9on","year":"2020","journal-title":"Microorganisms"},{"key":"B102","doi-asserted-by":"publisher","first-page":"ofab311","DOI":"10.1093\/ofid\/ofab311","article-title":"Cefiderocol Activity against Clinical pseudomonas Aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance","volume":"8","author":"Simner","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"e00951","DOI":"10.1128\/JCM.00951-20","article-title":"Cefiderocol Antimicrobial Susceptibility Testing Considerations: The Achilles Heel of the Trojan Horse?","volume":"59","author":"Simner","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"e01040","DOI":"10.1128\/AAC.01040-18","article-title":"Efficacy of Humanized Cefiderocol Exposures over 72 hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model","volume":"63","author":"Stainton","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/phar.2334","article-title":"Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report","volume":"39","author":"Stevens","year":"2019","journal-title":"Pharmacotherapy"},{"key":"B106","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jgar.2021.04.019","article-title":"In Vitro activity of Cefiderocol and Comparators against Isolates of Gram-Negative Pathogens from a Range of Infection Sources: SIDERO-WT-2014-2018 Studies in Italy","volume":"25","author":"Stracquadanio","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B107","doi-asserted-by":"publisher","first-page":"e4472","DOI":"10.1093\/cid\/ciaa1909","article-title":"Evolution of Cefiderocol Non-susceptibility in Pseudomonas aeruginosa in a Patient without Previous Exposure to the Antibiotic","volume":"73","author":"Streling","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B108","doi-asserted-by":"publisher","first-page":"S649","DOI":"10.1093\/ofid\/ofaa439.1450","article-title":"1266. Characterization of Shifts in Minimum Inhibitory Concentrations during Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies","volume":"7","author":"Takemura","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B109","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1093\/jac\/dkaa370","article-title":"In Vitro activity of Rifabutin against 293 Contemporary Carbapenem-Resistant Acinetobacter Baumannii Clinical Isolates and Characterization of Rifabutin Mode of Action and Resistance Mechanisms","volume":"75","author":"Trebosc","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"B110","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1093\/jac\/dkz318","article-title":"Successful Treatment with Cefiderocol for Compassionate Use in a Critically Ill Patient with XDR Acinetobacter Baumannii and KPC-Producing Klebsiella pneumoniae: a Case Report","volume":"74","author":"Trecarichi","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"B111","doi-asserted-by":"crossref","DOI":"10.26226\/morressier.56d6be7ad462b80296c97db1","article-title":"S-649266, a Novel Siderophore Cephalosporin: In Vitro Combination Effect of S-649266 and Other Antibiotics against Gram-Negative Bacteria","author":"Tsuji","year":"2016"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e1754","DOI":"10.1093\/cid\/ciaa1847","article-title":"Cefiderocol for the Treatment of Adult and Pediatric Patients with Cystic Fibrosis and Achromobacter Xylosoxidans Infections","volume":"73","author":"Warner","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B113","volume-title":"Global Priority List of Antibiotic Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics","author":"Tacconelli","year":"2017"},{"key":"B114","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus High-Dose, Extended-Infusion Meropenem for the Treatment of Gram-Negative Nosocomial Pneumonia (APEKS-NP): a Randomised, Double-Blind, Phase 3, Non-inferiority Trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"B115","doi-asserted-by":"publisher","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In Vitro activity of Cefiderocol against a Broad Range of Clinically Important Gram-Negative Bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"B116","article-title":"In Vitro activity of Cefiderocol against Gram-Negative Clinical Isolates Collected from Asia and South Pacific in 2014-2016 (SIDERO-CR Study)","author":"Yamano","year":"2017"},{"key":"B117","doi-asserted-by":"publisher","first-page":"S730","DOI":"10.1093\/ofid\/ofaa439.1636","article-title":"1455. Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies","volume":"7","author":"Yamano","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"S805","DOI":"10.1093\/ofid\/ofaa439.1806","article-title":"1626. Synergistic Effect of Cefiderocol with Other Antibiotics against PER-Producing Acinetobacter Baumannii Isolates from the Multinational SIDERO-WT Studies","volume":"7","author":"Yamano","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B119","doi-asserted-by":"publisher","first-page":"S728","DOI":"10.1093\/ofid\/ofaa439.1633","article-title":"1452. Molecular Profile of \u03b2-Lactamase Genes and Siderophore-dependent Iron Transporter Genes of Cefiderocol High MIC Isolates from SIDERO-WT Studies","volume":"7","author":"Yamano","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e0092421","DOI":"10.1128\/AAC.00924-21","article-title":"Extensively Drug-Resistant Acinetobacter Baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination","volume":"65","author":"Zaidan","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B121","doi-asserted-by":"publisher","first-page":"e00203","DOI":"10.1128\/AAC.00203-21","article-title":"Novel Specific Metallo-\u03b2-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive Enterobacterales","volume":"65","author":"Zalacain","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"B122","doi-asserted-by":"publisher","first-page":"ofaa185","DOI":"10.1093\/ofid\/ofaa185","article-title":"Cefiderocol for Extensively Drug-Resistant Gram-Negative Bacterial Infections: Real-World Experience from a Case Series and Review of the Literature","volume":"7","author":"Zingg","year":"2020","journal-title":"Open Forum Infect. Dis."}],"updated-by":[{"DOI":"10.3389\/fphar.2022.976792","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.896971\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T06:24:59Z","timestamp":1660803899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.896971\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":122,"alternative-id":["10.3389\/fphar.2022.896971"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.896971","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,12]]},"article-number":"896971"}}